Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J.F., Schlingemann R.O., Axer-Siegel R., Wiedemann P., Simader C., Gekkieva M., Weichselberger A.; EXCITE Study Group

Ophthalmology. 2011;118(5):831-9.

2011